Back to search
FDAFDA · Food and drugs·Recall number D-0177-2021

Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979

Published January 6, 2021 · Recall initiated: December 17, 2020

Summary

FDA records drug Class II recall D-0177-2021, published January 6, 2021 and initiated December 17, 2020. Recalling firm: Imprimis NJOF, LLC; Status: Terminated; Reported quantity: 6520 vials; Lot: Lot#: 20JUN010, Exp 5/12/21. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
U.S.A. Nationwide
Lot
Lot#: 20JUN010, Exp 5/12/21
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979 recalled?

Yes. FDA published recall D-0177-2021 on January 6, 2021. Reported hazard: Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit